[go: up one dir, main page]

IN2015DN02367A - - Google Patents

Info

Publication number
IN2015DN02367A
IN2015DN02367A IN2367DEN2015A IN2015DN02367A IN 2015DN02367 A IN2015DN02367 A IN 2015DN02367A IN 2367DEN2015 A IN2367DEN2015 A IN 2367DEN2015A IN 2015DN02367 A IN2015DN02367 A IN 2015DN02367A
Authority
IN
India
Prior art keywords
ipa
shigella
plasmid
strain
genes
Prior art date
Application number
Other languages
English (en)
Inventor
Gabor; Nagy
Tamas; Henics
Valeria; Szijarto
Eszter; Nagy
Original Assignee
Eveliqure Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eveliqure Biotechnologies Gmbh filed Critical Eveliqure Biotechnologies Gmbh
Publication of IN2015DN02367A publication Critical patent/IN2015DN02367A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0283Shigella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
IN2367DEN2015 2012-09-06 2013-09-05 IN2015DN02367A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12183347 2012-09-06
PCT/EP2013/068365 WO2014037440A2 (en) 2012-09-06 2013-09-05 A novel live attenuated shigella vaccine

Publications (1)

Publication Number Publication Date
IN2015DN02367A true IN2015DN02367A (he) 2015-09-04

Family

ID=46826297

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2367DEN2015 IN2015DN02367A (he) 2012-09-06 2013-09-05

Country Status (16)

Country Link
US (1) US9730991B2 (he)
EP (3) EP3978013A3 (he)
JP (1) JP6329544B2 (he)
KR (3) KR20210018542A (he)
CN (1) CN104797268B (he)
AU (1) AU2013311670B2 (he)
BR (1) BR112015004775A2 (he)
CA (1) CA2883652C (he)
DK (1) DK2879700T3 (he)
EA (1) EA031812B1 (he)
ES (1) ES2636897T3 (he)
IL (1) IL237508B2 (he)
IN (1) IN2015DN02367A (he)
MX (1) MX358201B (he)
SG (1) SG11201501697UA (he)
WO (1) WO2014037440A2 (he)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015091280A1 (en) * 2013-12-20 2015-06-25 Basf Se A process for production of a protein of interest in a microbial host organism
WO2016171524A1 (ko) * 2015-04-24 2016-10-27 국제백신연구소 이질의 치료 또는 예방용 백신 조성물
MX2019006105A (es) * 2016-11-25 2019-08-21 Glaxosmithkline Biologicals Sa Conjugados de vmen-antigeno y uso de los mismos.
EP3773700A4 (en) * 2018-04-03 2022-01-05 University of Maryland, Baltimore IMPROVED MULTIVALENT VACCINE AGAINST SHIGELLA-E. ENTERTOXINOGENIC COLI
CN108410790B (zh) * 2018-05-24 2019-05-14 中国人民解放军军事科学院军事医学研究院 ebgR基因敲除重组志贺氏菌的制备及应用
MX2023004359A (es) 2020-10-14 2023-07-06 Eveliqure Biotechnologies Gmbh Preparacion vacunal de shigella de dosis elevada.
CA3203697A1 (en) * 2020-12-29 2022-07-07 Jesus Maria Osorio Arguello Immunogenic and vaccine compositions against swine dysentery
CN114990042A (zh) * 2022-06-17 2022-09-02 南昌大学 一种含有能表达痢疾志贺氏菌o抗原的脂多糖的沙门菌、制备方法及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877159A (en) * 1995-05-03 1999-03-02 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same
US6136542A (en) * 1998-05-13 2000-10-24 Institut Pasteur Method for screening for inhibitors and activators of type III secretion machinery in gram-negative bacteria
US6399074B1 (en) 1998-07-24 2002-06-04 Megan Health, Inc. Live attenuated salmonella vaccines to control avian pathogens
US6713073B1 (en) * 1998-07-24 2004-03-30 Megan Health, Inc. Method of vaccination of newly hatched poultry
EP1198245B1 (en) * 1998-09-30 2004-08-25 Walter Reed Army Institute of Research Use of purified invaplex from gram negative bacteria as a vaccine
US7381557B2 (en) * 2003-04-07 2008-06-03 Tufts University Compositions and methods for bacterial immunity and secretion of proteins
WO2005116063A1 (en) * 2004-05-24 2005-12-08 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Live, oral vaccine for protection against shigella dysenteriae serotype 1
CA2563214A1 (en) * 2006-10-12 2008-04-12 Institut Pasteur Shigella ipad protein and its use as a potential vaccine against shigella infection
WO2010132764A2 (en) * 2009-05-14 2010-11-18 Northwestern University Live-attenuated compositions for bacterial infections
EP2485752A4 (en) * 2009-10-09 2013-07-31 Univ South Dakota VACCINES WITH ENTEROTOXY E. COLI FUSION PROTEINS

Also Published As

Publication number Publication date
EP3978013A2 (en) 2022-04-06
SG11201501697UA (en) 2015-04-29
JP6329544B2 (ja) 2018-05-23
MX2015002813A (es) 2015-08-20
IL237508B2 (he) 2023-04-01
US9730991B2 (en) 2017-08-15
EP3238741A1 (en) 2017-11-01
US20150246107A1 (en) 2015-09-03
KR102071743B1 (ko) 2020-01-31
CA2883652C (en) 2020-04-14
EP2879700B1 (en) 2017-06-07
WO2014037440A2 (en) 2014-03-13
CN104797268B (zh) 2018-05-01
JP2015532655A (ja) 2015-11-12
KR20210018542A (ko) 2021-02-17
EP2879700A2 (en) 2015-06-10
BR112015004775A2 (pt) 2017-11-21
IL237508B (he) 2022-12-01
IL237508A0 (he) 2015-04-30
DK2879700T3 (en) 2017-09-11
EA201500279A1 (ru) 2015-08-31
ES2636897T3 (es) 2017-10-10
MX358201B (es) 2018-08-03
AU2013311670B2 (en) 2018-04-05
KR20190110645A (ko) 2019-09-30
KR20150048771A (ko) 2015-05-07
WO2014037440A3 (en) 2014-10-02
EP3978013A3 (en) 2022-07-06
EA031812B1 (ru) 2019-02-28
CA2883652A1 (en) 2014-03-13
CN104797268A (zh) 2015-07-22
AU2013311670A1 (en) 2015-03-05

Similar Documents

Publication Publication Date Title
IN2015DN02367A (he)
CY1119895T1 (el) Εμβολια βιοπροϊοντος συζευξης καψικων gram-θετικων βακτηριδιων
MX346475B (es) Peptidos inmunogenicos monomericos y multimericos.
PH12013502621A1 (en) Vaccine composition comprising an inactivated chikungunya virus strain
BR112014033046A2 (pt) linhagem mutante atenuada de salmonella typhi, vacina de dna e vacina de dna vxm01
NZ630869A (en) Compositions and methods for dengue virus chimeric constructs in vaccines
PH12014502855B1 (en) Attenuated streptococcus suis vaccines and methods of making and use thereof
MX2023006203A (es) Vacunas novedosas contra el virus de zika.
EA201692359A1 (ru) Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса
GB2483595A (en) Recombinant bacterium and methods of antigen and nucleic acid delivery
MX2013010620A (es) Adenovirus de aves del serotipo 4 (fadv-4) no patogénico y vector viral del mismo.
MX2016007939A (es) Nueva vacuna de adn dirigida contra msln para la inmunoterapia de cancer.
PH12015500956A1 (en) Novel mucosal adjuvants and delivery systems
PH12014501388A1 (en) A recombinant koi herpesvirus (khv) and vaccine for the prevention of a disease caused by khv
MX2017005661A (es) Celulas de mamifero que expresan antigenos de citomegalovirus.
MA37749A1 (fr) Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine
BR112016028936A2 (pt) atenuação viral adaptada ao frio (cava) e cepas de poliovírus atenuadas inovadoras
WO2012003320A3 (en) Flavivirus host-range mutations and uses thereof
PH12017500407A1 (en) Streptococcus agalactiae antigens associated with strains virulent in fish
MX374919B (es) ANTÍGENOS Y COMBINACIONES DE ANTÍGENOS PARA USARSE PARA ELEVAR LA RESPUESTA INMUNE CONTRA Haemophilus influenzae.
IN2013CN01528A (he)
NZ595662A (en) Auxotrophic, recombinant bcg strain pasteur and use thereof for combating human infections caused by parasites
MX2023009696A (es) Metodos y composiciones para chlamydia atenuada como vacuna y vector.
Zhang et al. Effects of the deletion of RsbV gene on virulence of Listeria monocytogenes
RU2015146604A (ru) ДНК-конструкция, кодирующая модифицированный вариант протективного антигена Bacillus anthracis